Evidence map›Paper›PMID 38039407›Full record

ArticleEuropean journal of immunology2024

Zfp36l1 establishes the high-affinity CD8 T-cell response by directly linking TCR affinity to cytokine sensing.

Georg Petkau, Twm J Mitchell, Marian Jones Evans, Louise Matheson, Fiamma Salerno, Martin Turner

Open access · hybridAbstract read
In one paragraph

Article in European journal of immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Spatiotemporal CD8Cancer science · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Georg PetkauThe Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Twm J MitchellThe Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Marian Jones EvansThe Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Louise MathesonThe Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Fiamma SalernoThe Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.
Martin TurnerThe Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom.ORCID 0000-0002-3801-9896
Babraham Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BB/P01898X/1Biotechnology and Biological Sciences Research Council BBS/E/B/000C0407Biotechnology and Biological Sciences Research Council BBS/E/B/000C0428Wellcome TrustWellcome Trust 200823/Z/16/ZWellcome Trust 226660/Z/22/Z
6 · The paper itself

Abstract

How individual T cells compete for and respond to IL-2 at the molecular level, and, as a consequence, how this shapes population dynamics and the selection of high-affinity clones is still poorly understood. Here we describe how the RNA binding protein ZFP36L1, acts as a sensor of TCR affinity to promote clonal expansion of high-affinity CD8 T cells. As part of an incoherent feed-forward loop, ZFP36L1 has a nonredundant role in suppressing multiple negative regulators of cytokine signaling and mediating a selection mechanism based on competition for IL-2. We suggest that ZFP36L1 acts as a sensor of antigen affinity and establishes the dominance of high-affinity T cells by installing a hierarchical response to IL-2.

Indexed as

CytokinesReceptors, Antigen, T-CellCD8-Positive T-LymphocytesClone CellsInterleukin-2CytokinesInterleukin-2Receptors, Antigen, T-CellCD8 T cellsRNA binding proteinsT cell activationTCR affinity

Identifiers

PMID38039407
PMCPMC11146077
OpenAlexW4389258725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.